by Ethan Faverino | Apr 30, 2026 | News
By Ethan Faverino |
A new national poll conducted by Pulse Decision Science reveals that pharmaceutical reform represents a powerful and politically advantageous issue for Republican candidates heading into this election cycle.
The data shows the issue effectively consolidates support within the GOP base during primaries while delivering meaningful gains among independent and battleground voters in general elections.
The poll highlights near-universal frustration with the high costs of prescription drugs, creating a rare opportunity for Republicans to claim ownership of an issue that resonates deeply across demographic and partisan lines.
According to the survey, 84% of voters report using prescription medication, underscoring how broadly the issue affects American households. Cost pressures are forcing significant behavioral changes, with 55% of respondents admitting they have skipped doses, turned to over-the-counter alternatives, or ignored doctor recommendations due to high prices.
These coping behaviors are particularly common among younger women, lower-education voters, and independents/moderates.
Voters across the political spectrum overwhelmingly attribute rising drug prices to pharmaceutical industry practices rather than investments in innovation. Major factors cited include:
- Increasing profits: 81%
- Rising executive compensation: 76%
- Unethical business practices: 70%
By contrast, only 52% of voters view research and development costs as a major driver of prices—the weakest factor identified by a wide margin.
This perception creates fertile ground for messaging focused on corporate greed, price gouging, and unfair practices, which the poll indicates resonates strongly even with the Republican base.
When voters are presented with a candidate who supports specific, targeted pharmaceutical reforms—including Most Favorable Nation (MFN) pricing, patent reform, and measures to increase competition—that candidate sees a net +5-point gain in overall support.
Notable gains were recorded among key subgroups:
- Hispanics: +10 points
- High-propensity general election voters (3 of 4 voting history): +9 points
- Women 55 and older: +7 points
- Voters in lean Democratic Congressional districts: +7 points
- High school education or less: +7 points
- Republicans: +6 points
- Conservatives: +6 points
- Bachelor’s degree holders: +6 points
These shifts demonstrate that pharmaceutical reform serves both a base-unifying issue and a tool for expanding appeal in competitive general election environments.
The poll further shows that framing pharmaceutical reform through an “America First” lens is especially powerful in Republican primaries. Fully 89% of GOP primary voters indicated they are more likely to support a candidate who prioritizes codifying President Trump’s Most Favorable Nation Executive Order.
When paired with messaging that emphasizes America-First pricing, the issue delivers strong consolidation within the Republican coalition. Key subgroup gains in the primary context include:
- Males 18-34: +13 points
- Voters in lean Republican Congressional districts: +11 points
- Mid-turnout voters (2 of 4 voting history): +10 points
- Self-described “Not So Strong” Republicans: +10 points
The findings arrive as the Trump administration continues to focus on delivering tangible results on pharmaceutical pricing. On April 23, 2026, President Trump announced the 17th agreement with a major pharmaceutical manufacturer—this time with Regeneron—bringing MFN-style pricing to American patients.
The deal provides every State Medicaid program access to MFN prices on Regeneron products, delivering hundreds of millions in savings. It covers 86% of the branded drug market across 17 leading manufacturers and includes commitments to end foreign freeloading on American innovation.
Key provisions include significant price reductions, such as lowering the price of Regeneron’s cholesterol medication, Praluent, from $537 to $225 when purchased through TrumpRx.
Additionally, Regeneron’s new gene therapy for a rare form of genetic deafness, Otarmeni, will be provided at no cost to American families. The company also committed to a $27 billion investment in U.S. research, development, and manufacturing by 2029, contributing to a total of $448 billion in pharmaceutical investments secured under President Trump in just 15 months.
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
by Ethan Faverino | Feb 5, 2026 | News
By Ethan Faverino |
Arizona State Senator Janae Shamp (R-LD29) has introduced legislation to safeguard patients and local pharmacies from the growing influence of “corporate middlemen” in the prescription drug market.
Senate Bill 1545 prohibits pharmacy benefit managers (PBMs) from owning or holding any direct or indirect interest in retail pharmacies in Arizona. The bill addresses a fundamental conflict of interest that allows PBMs—mediators between insurers, drug manufacturers, pharmacies, and patients—to steer prescriptions to their affiliated pharmacies, under-reimburse independent competitors, drive up costs, and reduce patients’ choice.
“Arizonans deserve transparency and fairness in their prescription drug costs,” stated Senator Shamp. “PBMs were created to manage benefits — not to own pharmacies, control the rules, and profit off the entire system. PBMs were never meant to be both the referee and the player.”
PBMs control key aspects of prescription drug access, including which medications are covered, where prescriptions can be filled, and the reimbursement rates to pharmacies. When PBMs own pharmacies, they can prioritize their own outlets, quietly eliminate local and independent pharmacies, and inflate overall drug costs.
“This bill sends a clear message: our healthcare system exists to serve patients, not corporate profits,” added Shamp. “When the middleman becomes the gatekeeper, prices rise, choices narrow, and local pharmacies are pushed out. SB 1545 ends that self-dealing and puts patients back in control. This bill is about fairness, transparency, and making sure Arizona’s healthcare system works for families — not for corporate executives gaming the system behind closed doors.”
The legislation directs the Arizona State Board of Pharmacy to enforce compliance by revoking or refusing to renew any permits held in violation of this measure.
To protect patient access, the bill establishes safeguards for rare, orphan, or limited-distribution medications that might otherwise become unavailable. The Board is authorized to issue limited-service pharmacy permits in these cases and to convert existing permits as needed for a minimum of 90 days while assessing ongoing market availability. The measure also allows temporary extensions of pharmacy permits for facilities that provide critical services during pending sales to eligible buyers.
The legislation sets a phased implementation, beginning with an initial assessment of all active pharmacy permits as of July 1, 2026. At least 90 days before January 1, 2027, the Board must send written notice to any permit holders reasonably believed to be in violation, and affected pharmacies must then provide written notice to their patients and prescribing providers at least 60 days before the effective date of December 31, 2026.
Ethan Faverino is a reporter for AZ Free News. You can send him news tips using this link.
by Corinne Murdock | Mar 7, 2023 | News
By Corinne Murdock |
Attorney General Kris Mayes revealed over the weekend that her office has been encouraging pharmacies to give out abortion pills.
Mayes issued the remarks in an interview with MSNBC last Saturday discussing a multistate lawsuit against the FDA for imposing allegedly burdensome regulation on mifepristone, a drug used for abortions. Joining Mayes on the live interview were Attorneys General Kathy Jennings (Delaware) and Ellen Rosenblum (Oregon).
“We are one of those states who have actually encouraged Walgreens, and CVS, and other pharmacies to continue to offer the medication despite that pressure by Republican AGs,” said Mayes.
The attorney general criticized GOP attorneys general in other states, specifically Texas, for opposing abortion.
“You see that effort by some of those GOP attorneys general to continue to try to limit the access of women to abortion in every possible way they can find,” said Mayes. “Despite the fact that Roe was overturned, and it was sent back to the states, they’re still making these efforts in states to limit a woman’s access to abortion. And that’s why actions by Democratic AGs largely are so important. We’re going to continue to fight going forward.”
A total of 12 states joined the lawsuit against the FDA: Rosenblum and Washington Attorney General Bob Ferguson led the lawsuit, joined by Nevada, Delaware, Illinois, Connecticut, Colorado, Vermont, New Mexico, and Rhode Island. The states requested a preliminary injunction to halt the restrictions on mifepristone, which require that health care providers be specially certified by the drug distributor in advance, patients and providers be willing to sign an agreement certifying that the patient has decided to take drugs to end their pregnancy, and pharmacies be specially certified to fill a prescription and dispense the drug.
Mayes claimed in a press release on the FDA lawsuit that mifepristone is safe. The FDA restrictions, specifically a risk evaluation mitigation strategy (REMS), ensure that mifepristone’s benefits outweigh any risks. Congressional Research Service (CRS) noted that the FDA is looking to roll back these REMS regulations.
During the MSNBC interview, Mayes also revealed that she plans to set up a “reproductive rights” unit in her office. She further added that she wouldn’t prosecute anyone for providing an abortion, even if they broke state law, and would do everything in her power to prevent county attorneys from enforcing abortion law. Mayes noted that she’s able to defy law because she and Gov. Katie Hobbs are Democrats.
“You do have a state like Arizona that has a Republican legislature, thankfully we have a Democratic attorney general and a Democratic governor now who will stop that kind of thing,” said Mayes. “I have been clear here in Arizona that we will never prosecute a woman, a doctor, a midwife, a nurse for abortion. But we have 15 county attorneys in Arizona and I’ve been clear also that I will fight any effort by a county attorney to prosecute.”
Mayes’ pledge to not prosecute aligns with her campaign promise to oppose abortion law.
Mayes claimed abortion is a constitutional right, and indicated that she would take legal action to fight current abortion restrictions. Arizona law currently bans abortion after 15 weeks.
“We are prepared to take action in support of those constitutional rights,” said Mayes.
At least three cities have effectively decriminalized abortion: Tucson, Phoenix, and, most recently, Flagstaff.
Corinne Murdock is a reporter for AZ Free News. Follow her latest on Twitter, or email tips to corinne@azfreenews.com.
Page 1 of 11
